IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines1,2

Neoplasia

Volumn 14, Issue 3, 2012, Pages 178-189

  Jain, Garima ^a   Voogdt, Cornelia ^a   Tobias, Anna ^a   Spindler, Klaus Dieter ^a   Möller, Peter ^a   Cronauer, Marcus V ^a   Marienfeld, Ralf B ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYLAMINO) 1, 8 DIMETHYLIMIDAZO [1, 2 A] QUINOXALINE; ANDROGEN RECEPTOR; ANDROSTANOLONE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM;

EID: 84859149259     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111444     Document Type: Article

References (34)

1. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, and Visakorpi T (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61, 3550-3555.
2. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, and Feldman D (2000). Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6, 703-706.
3. Schutz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, and Schrader M (2011). Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 6, e25341.
4. Oeckinghaus A and Ghosh S (2009). The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1, a000034.
5. Scheidereit C (2006). IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 25, 6685-6705.
6. Karin M (2006). Nuclear factor-κB in cancer development and progression. Nature 441, 431-436.
7. Karin M (2008). The IκB kinase-a bridge between inflammation and cancer. Cell Res 18, 334-342.
8. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, and Saad F (2004). Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10, 8460-8464.
9. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, and Budunova IV (2002). The role of IKK in constitutive activation of NF-κB tran- scription factor in prostate carcinoma cells. J Cell Sci 115, 141-151.
10. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, et al. (2008). The nuclear factor-κB pathway con- trols the progression of prostate cancer to androgen-independent growth. Cancer Res 68, 6762-6769.
11. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, and Saad F (2005). Nuclear localisation of nuclear factor-κB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93, 1019-1023.
12. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, and Rabson AB (2002). Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 52, 183-200.
13. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, and Cheng L (2004). Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10, 5501-5507.
14. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, et al. (2009). NF-κB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175, 489-499.
15. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, and Karin M (2010). B-cell- derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302-305.
16. Yemelyanov A, Gasparian A, Lindholm P, Dang L, Pierce JW, Kisseljov F, Karseladze A, and Budunova I (2006). Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25, 387-398.
17. May MJ, Marienfeld RB, and Ghosh S (2002). Characterization of the IκB-kinase NEMO binding domain. J Biol Chem 277, 45992-46000.
18. Marienfeld RB, Palkowitsch L, and Ghosh S (2006). Dimerization of the IκB kinase-binding domain of NEMO is required for tumor necrosis factor α-induced NF-κB activity. Mol Cell Biol 26, 9209-9219.
19. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, and Gao AC (2010). Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells. Cancer Res 70, 3309-3319.
20. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, and Stringer B (2004). Expression of nuclear factor-κB and IκBα proteins in prostatic adenocarcinomas: correlation of nuclear factor-κB immunoreactivity with disease recurrence. Clin Cancer Res 10, 2466-2472.
21. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, et al. (2003). BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem 278, 1450-1456.
22. Nadiminty N, Chun JY, Lou W, Lin X, and Gao AC (2008). NF-κB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 68, 1725-1733.
23. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, et al. (2002). Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-29314.
24. Rytinki MM, Kaikkonen S, Sutinen P, and Palvimo JJ (2011). Analysis of androgen receptor SUMOylation. Methods Mol Biol 776, 183-197.
25. Mukherjee S, Thomas M, Dadgar N, Lieberman AP, and Iniguez-Lluhi JA (2009). Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J Biol Chem 284, 21296-21306.
26. Chymkowitch P, May N, Charneau P, Compe E, and Egly JM (2011). The phos- phorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J 30, 468-479.
27. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, and Karin M (2007). Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 446, 690-694.
28. Blok LJ, de Ruiter PE, and Brinkmann AO (1996). Androgen receptor phosphory- lation. Endocr Res 22, 197-219.
29. Wang G and Sadar MD (2006). Amino-terminus domain of the androgen recep- tor as a molecular target to prevent the hormonal progression of prostate cancer. J Cell Biochem 98, 36-53.
30. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, and Murphy LC (2006). Estrogen receptor-α phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 66, 10162-10170.
31. Schutz SV, Cronauer MV, and Rinnab L (2010). Inhibition of glycogen synthase kinase-3β promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem 109, 1192-1200.
32. Rinnab L, Schutz SV, Diesch J, Schmid E, Kufer R, Hautmann RE, Spindler KD, and Cronauer MV (2008). Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? Neoplasia 10, 624-634.
33. Nadiminty N, Chun JY, Hu Y, Dutt S, Lin X, and Gao AC (2007). LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun 359, 379-384.
34. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, and Gao AC (2006). Stat3 activation of NF-{κ}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA 103, 7264-7269.